View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 14, 2020

University of Birmingham to launch CATALYST trial for Covid-19

The University of Birmingham in the UK is set to launch the CATALYST trial this week to evaluate various drugs for the treatment of Covid-19 patients.

CATALYST will involve drugs targeting the most serious symptoms. This mechanism is expected to mitigate disease severity, decreasing the number of patients requiring intensive care admission.

A series of new drugs will be tested in the trial, including existing medicines for cancer and inflammatory diseases such as rheumatoid arthritis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena